Microcap Biotech Stock RenovoRx is Shooting Higher Today: Here's Why

RenovoRx Inc RNXT presented new data on progression-free survival (PFS) from the pivotal Phase 3 open-label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC). 

The interim data was featured at the 2023 ESMO World Congress on Gastrointestinal Cancer.

The interim analysis demonstrated an eight-month median PFS benefit, 15 versus 7 months, in delaying cancer progression for patients receiving treatment with RenovoGem versus standard-of-care.

Related: RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care. 

PFS is the measure of the length of time from study randomization to either death or disease progression.

The study is designed to randomize 114 patients (57 in each arm), all receiving upfront induction chemotherapy and stereotactic body radiation therapy (SBRT). 

The TIGeR-PaC Data Monitoring Committee met and determined that the interim data is promising and warrants the continuation of this pivotal trial. 

As of the analysis date, 45 patients from U.S. sites had been randomized in this trial, and the survival status of all subjects was used for the analysis.

Twenty-three patients were randomized to the intra-arterial (IA) gemcitabine (RenovoGem investigational treatment) arm and 22 patients to the continuation of intravenous (IV) gemcitabine and nab-paclitaxel (standard-of-care) control arm.

The median PFS data in the IV gemcitabine and nab-paclitaxel control arm was 7 versus 15 months in the IA RenovoGem arm.

Patients had a greater than 65% reduction in adverse events compared to the control arm.

The median overall survival in the IV gemcitabine and nab-paclitaxel control arm was ten months versus 16 months in the IA RenovoGem arm.

TIGeR-PaC is currently enrolling unresectable LAPC patients at several sites across the U.S. 

Price Action: RNXT shares are up 8.93% at $2.44 on the last check Thursday.